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Background  and  purpose      Pharmacological  prophylaxis  can 
reduce the risk of deep venous thrombosis (DVT), pulmonary 
embolism (PE), and death, and it is recommended 10–35 days 
after total hip arthroplasty (THA) and at least 10 days after total 
knee  arthroplasty  (TKA).  However,  early  mobilization  might 
also reduce the risk of DVT and thereby the need for prolonged 
prophylaxis, but this has not been considered in the previous lit-
erature. Here we report our results with short-duration phar-
macological prophylaxis combined with early mobilization and 
reduced hospitalization.
Patients and methods   1,977 consecutive, unselected patients 
were operated with primary THA, TKA, or bilateral simultane-
ous TKA (BSTKA) in a well-described standardized fast-track 
set-up from 2004–2008. Patients received DVT prophylaxis with 
low-molecular-weight heparin starting 6–8 h after surgery until 
discharge. All re-admissions and deaths within 30 and 90 days 
were analyzed using the national health register, concentrating 
especially on clinical DVT (confirmed by ultrasound and elevated 
D-dimer), PE, or sudden death. Numbers were correlated to days 
of prophylaxis (LOS).
Results   The mean LOS decreased from 7.3 days in 2004 to 
3.1 days in 2008. 3 deaths (0.15%) were associated with clotting 
episodes and overall, 11 clinical DVTs (0.56%) and 6 PEs (0.30%) 
were  found. The  vast  majority  of  events  took  place  within  30 
days; only 1 death and 2 DVTs occurred between 30 and 90 days. 
During the last 2 years (854 patients), when patients were mobi-
lized within 4 h postoperatively and the duration of DVT pro-
phylaxis was shortest (1–4 days), the mortality was 0% (95% CI: 
0–0.5). Incident cases of DVT in TKA was 0.60% (CI: 0.2–2.2), in 
THA it was 0.51% (CI: 0.1–1.8), and in BSTKA it was 0% (CI: 
0–2.9). Incident cases of PE in TKA was 0.30% (CI: 0.1–1.7), in 
THA it was 0% (CI: 0–1.0), and in BSTKA it was 0% (CI: 0–2.9).
Interpretation   The risk of clinical DVT, and of fatal and non-
fatal PE after THA and TKA following a fast-track set-up with 
early mobilization, short hospitalization, and short duration of 
DVT prophylaxis compares favorably with published regimens 
with extended prophylaxis (up to 36 days) and hospitalization up 
to 11 days. This calls for a reconsideration of optimal duration of 
chemical thromboprophylaxis.
 
Total hip and knee arthroplasty (THA and TKA) are associ-
ated with perioperative risks including deep venous thrombo-
sis (DVT) and pulmonary embolism (PE)—both of which are 
manifestations of venous thromboembolism (VTE)—possibly 
leading to a post-thrombotic syndrome (PTS) or death. The 
mechanisms underlying VTE are not fully understood (Malone 
1977, Malone and Agutter 2006). Immobility with long hospi-
talization after surgery may be a contributory factor (Heit et al. 
2001, Seddighzadeh et al. 2007, Sharma et al. 2007). 
The recent evidence-based guidelines for DVT prophylaxis 
according to the American College of Chest Physicians con-
sist of at least 10 days of prophylaxis after TKA and THA, 
and preferably up to 35 days after THA (Geerts et al. 2008). 
The incidence of DVT has been found to have decreased over 
time, possibly as a result of increased and earlier mobilization 
(Xing et al. 2008). We therefore present our data on DVT, PE, 
and death after TKA, bilateral simultaneous TKA (BSTKA), 
and THA with a fast-track set-up with short DVT prophylaxis, 
early mobilization, and short hospitalization. 
Patients and methods
The fast-track set-up was implemented in 2003 and consists 
of optimized logistics and evidence-based clinical features (as 
described in detail below) (Husted et al. 2008). Optimization 
of logistics includes a homogenous ward with arthroplasty 
patients only, regular staff, high continuity, preoperative infor-
mation including intended length of stay (LOS), admission on 
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get dressed, to get in and out of bed, to get into and up from a 
chair, and to walk with crutches or better). 
Since then, all patients operated on with THA, TKA, bilat-
eral simultaneous TKA (BSTKA), and revisions have been 
enrolled in the program. We concentrated on pain treatment 
and  early  mobilization,  and  our  current  research  involves 
refinement of these tools for improving convalescence in order 
to reduce length of stay. Thus, LOS has been reduced in incre-
ments. From 2004 to 2006 the intended LOS was around 5 
days, and from 2007 to 2008 the intended LOS was 3 days 
when local infiltration analgesia (LIA) was introduced, allow-
ing patients to be mobilized with only moderate pain (Ander-
sen et al. 2008a, b, c, Kerr and Kohan 2008).
The patients were consecutive and unselected, and all of 
them were operated using regional anesthesia—from 2004 to 
2006 epidural for TKAs and spinal for THAs, but from 2007 
all with spinal anesthesia with 2 mL hyperbaric bupivacaine 
0.5% (TKA), 2.5 mL plain bupivacaine 0.5% (THA), and 3 
mL plain bupivacaine 0.5% (BSTKA) combined with local 
infiltration analgesia (LIA) (Andersen et al. 2008a). Also, a 
standardized program in the operating theater was followed, 
including  fluid  administration  (Holte  et  al.  2007),  use  of 
tranexamic acid (Benoni and Fredin 1996, Husted et al. 2003), 
small standard incisions (posterior for THA, midline skin and 
medial parapatellar for TKA), no drains, use of compression 
bandages (Andersen et al. 2008c), and cooling (Kullenberg 
et al. 2006). Multimodal opioid-sparing analgesia (NSAID, 
paracetamol, gabapentin, local analgesia) together with early 
mobilization has facilitated the reduction in LOS (Andersen 
et al. 2009). 
All TKA patients were operated with a tricompartmental 
cemented prosthesis. Surgery was done in a bloodless field 
by using a femoral tourniquet (inflated to 100 mmHg above 
systolic blood pressure) from incision until cementation of the 
prosthesis was finished. 15 minutes before incision, 500 mg 
of intravenous tranexamic acid was administered and another 
500 mg just before tourniquet release.
 All THA patients were operated with an uncemented cup 
and either a cemented or an uncemented stem. 15 minutes 
before incision, 1,000 mg of intravenous tranexamic acid was 
administered. Immediate and full weight bearing was allowed 
after all operations.
Discharge criteria were strictly functional and all patients 
were discharged to their own homes. LOS was counted as 
number of nights of hospitalization after the operation.
 DVT prophylaxis consisted of low-molecular-weight hepa-
rin (LMWH) (enoxaparin 40 mg subcutaneously) starting 6–8 
h postoperatively and continuing once daily in the evening 
until discharge. No extended prophylaxis was given and no 
mechanical devices (including compression stockings) were 
used. No attempt was made to identify high-risk patients; all 
patients received the same regime.
Patients  were  mobilized  on  the  day  of  operation.  In  the 
period  2004–2006,  patients  were  mobilized  in  the  after-
noon or evening, but from 2007 the LIA technique made a 
more aggressive mobilization possible, usually within 2–4 h 
after the operation. The pain treatment consisted initially of 
NSAIDs  and  paracetamol—with  opioids  for  breakthrough 
pain—but since 2007, a standardized pain treatment has been 
given to all patients (gabapentin, paracetamol, celecoxib with 
oxycodone 10 mg on request) (Andersen et al. 2008a, b). 
All patients are registered in the National Health Register 
when they are operated and all re-admissions at any hospital 
in Denmark are registered. All records were scrutinized for 
re-admissions, and all re-admissions with DVT, PE, or death 
and also deaths without re-admission were analyzed and regis-
tered. All deaths were followed by autopsy except in one case, 
and the diagnosis was recorded and linked to the operation if a 
clotting episode was involved. In the case where autopsy was 
not performed, death was assumed to be linked to the opera-
tion. No patients were lost to follow-up, which was therefore 
100%.
Statistics
The study was presented to the ethical committee for the capi-
tal region. Numbers of incident cases are the cumulated cases, 
i.e. the number of new cases within a specified time period 
divided by the size of the population initially at risk. 95% con-
fidence intervals (CI) were calculated using the Wilson pro-
cedure without correction of continuity using the VassarStats 
website for statistical computation (faculty.vassar.edu/lowry/
VassarStats.html).  All  data  analyses  were  conducted  with 
SPSS for Windows, version 13.0.
Results
From 2004 through 2008, 1,977 operations were performed: 
947 THA, 784 TKA, and 246 BSTKA. Mean length of stay 
(LOS) decreased during the study period from 4.6 to 3.1 days 
for TKA, 6.3 to 3.9 days for THA, and 7.3 to 4.2 days for 
BSTKA.
Tables 1 and 2 show distribution of operations, LOS, and 
corresponding numbers of incident cases of DVT, PE, and 
death within 90 days. The figure shows the numbers of inci-
dent cases of DVT, PE, and death for each year with corre-
sponding mean LOS.
Table 1. Distribution of operations and length of stay (LOS)
  No. of operations  Length of stay
  All  TKA  BSTKA  THA  TKA  BSTKA  THA
2004  311  124  28  159  4.4  5.9  6.3
2005  378  167  32  179  4.6  6.0  5.3
2006  434  159  58  217  4.5  7.3  5.7
2007  433  182  52  199  3.1  4.2  4.2
2008  421  152  76  193  3.2  4.2  3.9
Total  1,977  784  246  947
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Deaths
From 2004 through 2008, 14 patients (0.71% (CI: 0.4–1.2)) 
died within 90 days of surgery: 3 in 2004 (mesenterial throm-
bosis (89 days), myocardial infarction (2 days), and sepsis/
pneumonia (27 days)); 3 in 2005 (hepatic cirrhosis and coma 
(28 days), perforated colon cancer (51 days), sudden death (1 
day, no autopsy)); 3 in 2006 (metastatic lung cancer (77 days), 
dysregulated warfarin treatment (resulting in massive bleed-
ing) for atrial fluttering (50 days), perforated gastric ulcer (22 
days)); 4 in 2007 (cardiomyopathy and failure (89 days), lung 
cancer (10 days), mechanical bowel obstruction (76 days), 
hepatic cirrhosis with esophageal bleeding (83 days)); and 
1 in 2008 (aortic stenosis, pulmonary insufficiency, and car-
diac failure (19 days)). Thus, 2 deaths in 2004 (1 THA and 1 
TKA) and 1 in 2005 (TKA)—and none in 2006–2008—may 
have been related to clotting episodes, giving an overall risk of 
VTE-related mortality of 0.15% (CI: 0.04–0.48). 
Pulmonary embolism
From 2004 through 2008, 6 patients had confirmed pulmonal 
embolism (PE) diagnosed by perfusion-ventilation lung scin-
tigraphy, with none in the BSTKA group, 4 in the TKA group, 
and 2 in the THA group leading to risks from 0% to 0.63%. All 
PE occurred before 30 days postoperatively. No patients died 
from PE (except the potential one with sudden unexplained 
death without autopsy in 2005). During the last 2 years with 
the shortest LOS, the risk of PE was 0.30% (CI: 0.1–1.7) after 
TKA and 0% (CI: 0–1.0) after THA. 
Table 2. Numbers and incidences (with 95% CI) of deep venous thrombosis (DVT), 
pulmonary embolism (PE), and death (D) within 90 days
 
  Number of  Incidences (CI)
  DVT  PE  D  DVT  PE  D
TKA
  2004  2  0  1  1.61 (0.4–5.7)  0      (0–3.0)  0.81 (0.1–4.4)
  2005  4  2  1  2.40 (0.9–6.0)  1.20 (0.3–4.3)  0.60 (0.1–3.3)
  2006  1  1  0  0.63 (0.1–3.5)  0.63 (0.1–3.5)  0      (0–2.4)
  2007  1  1  0  0.55 (0.1–3.1)  0.55 (0.1–3.1)  0      (0–2.1)
  2008  1  0  0  0.66 (0.1–3.6)  0      (0–2.5)  0      (0–2.5)            
  Total        1.15 (0.6–2.2)  0.51 (0.2–1.3)  0.26 (0.1–1.0)            
BSTKA
  2004  0  0  0  0      (0–12.1)  0      (0–12.1)  0      (0–12.1)
  2005  0  0  0  0      (0–10.7)  0      (0–10.7)  0      (0–10.7)
  2006  0  0  0  0      (0–6.2)  0      (0–6.2)  0      (0–6.2)
  2007  0  0  0  0      (0–6.9)  0      (0–6.9)  0      (0–6.9)
  2008  0  0  0  0      (0–4.8)  0      (0–4.8)  0      (0–4.8)            
  Total        0      (0–1.5)  0      (0–1.5)  0      (0–1.5)            
THA
  2004  0  1  1  0      (0–2.4)  0.63 (0.1–3.5)  0.63 (0.1–3.5)
  2005  0  1  0  0      (0–2.1)  0.56 (0.1–3.1)  0      (0–2.1)
  2006  0  0  0  0      (0–1.7)  0      (0–1.7)  0      (0–1.7)
  2007  1  0  0  0.50 (0.1–2.8)  0      (0–1.9)  0      (0–1.9)
  2008  1  0  0  0.52 (0.1–2.9)  0      (0.1–2.0)  0      (0.1–2.0)            
  Total        0.21 (0.1–0.8)  0.21 (0.1–0.8)  0.11 (0–0.6)
Numbers of incident cases of DVT, PE and death for each year with correspond-
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Deep venous thrombosis
11 clinical cases of DVT were found within 90 days from 2004 
through 2008 with the clinical diagnosis being confirmed by 
an elevated D-dimer result and a positive ultrasound exami-
nation: 9 in the TKA group (1.2%) and 2 in the THA group 
(0.2%). No DVT was seen in the BSTKA group. Only 2 cases 
of DVT were found between 30 and 90 days (1 THA, 1 TKA). 
None of the patients with DVT developed PE within 90 days, 
since all patients with PE had no clinical diagnosis of DVT. 1 
of 2 DVTs in THA was proximal to the knee joint, and 3 of 
9 DVTs in TKA. Combining the last 2 years with the shortest 
LOS, the risk of DVT in TKA was 0.6% (CI: 0.2–2.2) and 
0.51% (CI: 0.1–2.1) after THA. 
97 days of hospitalization for DVT/PE re-admissions were 
used in the TKA group (21 days, 55 days, 12 days, 8 days, 
and 1 day for the years 2004–2008, respectively), 0 days for 
the BSTKA group, and 28 days for the THA group (12 days, 
4 days, 0 days, 10 days, and 2 days for 2004–2008, respec-
tively). In addition, 80 patients were re-admitted for suspected 
DVT during the study period (46 TKAs, 1 BSTKA, and 33 
THAs), but the diagnosis was excluded by ultrasound and 
D-dimer measurements. 
Discussion
We found a very low risk of clinically symptomatic VTE and 
deaths potentially related to the operation in an unselected 
patient population with a consecutive set-up and 100% follow-
up for 90 days. We used the unique Danish National Health 
Register to record all national re-admissions and the Danish 
Personal Register to assess mortality. In Denmark, all patients 
with verified DVT are re-admitted and treated in hospital, so 
we believe that the numbers of incident cases we found are 
true risks and not underestimates of the real numbers—as no 
patients are treated initially for DVT in an outpatient setting. 
Also, all charts were scrutinized for all types of re-admission 
in order to avoid missing cases of VTE that were miscoded as 
other diagnoses for re-admission.
We found an overall risk of death potentially related to the 
operation of 0.15%, which compares favorably with the results 
of a recent study where 0.31% of patients died within 90 days 
of an operation with THA or TKA, and following 6 weeks 
of 150 mg aspirine daily as the only prophylaxis (Cusick and 
Beverland 2009). Also, the risk of death possibly resulting 
from clotting episodes found in the current study was lower or 
similar to those in all previously published studies where post-
operative mortality was validated, regardless of type (whether 
chemoprophylactic or mechanical) and duration of thrombo-
prophylaxis (up to 36 days) (Mantilla et al. 2002, Blom et al. 
2006, Tarity et al. 2006, Lachiewiicz and Soileau 2006, 2007, 
Samama et al. 2007, Eriksson et al. 2008, Aynardi et al. 2009, 
Lassen et al. 2009). 
Rebound activation of coagulation after cessation of pro-
phylaxis  may  play  a  role  in VTE  and  death  after  surgery. 
Rebound hypercoagulability has been described to occur after 
discontinuation of chemical prophylaxis (Kontny 1997, Cun-
diff 2008) based on continuous generation of platelets and 
thrombin after cessation of the prophylactic drug. Rebound 
hypercoagulability is estimated to account for 2% of patients 
having VTE in the first 2 months after discontinuing oral anti-
coagulants; it is also been found, however, that an increased 
duration of treatment with oral anticoagulants does not reduce 
the overall number of adverse events (Cundiff 2008). How-
ever, the low risk of VTE in our study suggests that rebound 
hypercoagulability may not be a problem after a few days of 
thromboprophylaxis.
The evidence-based guidelines for DVT prophylaxis accord-
ing to the American College of Chest Physicians involve at 
least 10 days of treatment after TKA and THA—and prefer-
ably up to 35 days after THA (Geerts et al. 2008). LMWH is 
recommended, and has been found to reduce the risk of VTE 
by 50%, whereas these guidelines do not support the sole use 
of aspirin as a prophylactic agent.
The antiplatelet effect of aspirin is, nevertheless, the reason 
for the use of this drug in many hospitals, in the USA espe-
cially but also in Europe. Cusick and Beverland (2009) advo-
cated prophylaxis with aspirin (150 mg daily for 6 weeks) only 
for the standard patient, except for patients with a prior history 
of PE. They concluded that: “…with modern surgical prac-
tice, elective hip and knee replacement should no longer be 
considered high-risk procedures.” Others have supported this 
belief. Thus, some propose differentiated DVT prophylaxis by 
identifying low- and high-risk patients after THA and TKA, 
balancing the need for prophylaxis against the risk of bleeding 
(Lachiewicz and Soileau 2006, 2007, Dorr et al. 2007). Such 
regimens have led to incidences of 0.25% for (non-fatal) PE 
after THA and TKA (Dorr et al. 2007), and 0.35% for PE after 
TKA and 0.7% after THA (Lachiewicz and Soileau 2006 and 
2007). These very low incidences are similar to our results on 
PE, although the patients were followed up for different peri-
ods of time (1–6 months vs. 90 days). 
Others have found incidences of PE after THA in the range 
0.1–0.7%  with  different  regimens,  with  prophylactic  treat-
ment from 10–14 days and up to 36 days of rivaroxoban or 
enoxaparin and up to 6 weeks of aspirin (Mantilla et al. 2002, 
Lachiewicz  and  Soileau  2006,  2007,  Eriksson  et  al.  2008, 
Lassen et al. 2008, Cusick and Beverland 2009). The rate 
of PE we found is similar to these incidences, although our 
patients were treated with enoxaparin for only a few days. 
The standardization in the use of regional analgesia and very 
early mobilization combined with short hospitalization may 
be important in achieving such low incidences of PE (Rodgers 
et al. 2000). 
DVT can lead to a post-thrombotic syndrome (PTS) with 
swelling, varicose veins, pain and discomfort, and hyperpig-
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to have a similar incidence with or without DVT, and with 
no  major  sequelae  after  ultrasonographically  proven  DVT 
(McAndrew  et  al.  2010);  nor  was  there  any  substantial 
increase in risk of PTS after asymptomatic proximal or distal 
DVT following TKA or THA (Lonner et al. 2006). Also, the 
largest study on the possibility of PTS after THA failed to find 
any predictors of PTS—including the infrequent occurrence 
of DVT (Mant et al. 2008).
We found risks of clinically proven and symptomatic DVT 
of 0.21% (THA) and 1.15% (TKA) during the 5-year period. 
Again,  these  figures  compare  favorably  with  studies  with 
longer treatment. Thus, 36 days of treatment with rivaroxa-
ban or enoxaparin after THA resulted in 0.3% and 0.5% risk 
of DVT, respectively (Eriksson et al. 2008), although LOS or 
mobilization was not accounted for. Treatment with the same 
chemoprophylaxis for 10–14 days after TKA led to 1.1% and 
2.2% risk of symptomatic DVT with a follow-up of 49 days at 
most (Lassen et al. 2008), combined with a mean LOS of 6.2 
and 6.3 days (the type of mobilization was not mentioned). 
A multicenter study with prolonged treatment with various 
types of chemoprophylaxis for 36 ± 9.8 days (59% of patients 
also used compression stockings) found 1.3% and 2.3% risk 
of clinically symptomatic DVT after THA and TKA, with a 
follow-up of 90 days (Samama et al. 2007). This study also 
found that lack of ambulation was predictive of VTE, as did 
a study on early mobilization where mobilization within 24 h 
from the operation resulted in a 30-fold reduction in the risk of 
postoperative DVT (Pearse et al. 2007). The very early ambu-
lation of our patients supported by our pain protocol with LIA 
(Andersen et al. 2008 a,b,c, 2009) may thus play an important 
role in reducing VTE.
Another  study  involving  6,639  THAs  and  8,326  TKAs 
found cumulative incidences of VTE of 1.8% and 2.3% (War-
wick et al. 2007). The data from 100 hospitals in 13 countries 
were pooled, with varying degrees of chemical and mechani-
cal prophylaxis. Median LOS varied from 3 to 11 days; more 
than one-third of the patients were discharged to rehabilitation 
facilities, and more than one-third of the patients had general 
anesthesia, reflecting the different approaches between depart-
ments. However, that study found a lack of compliance with 
the recommendations regarding the duration of prophylaxis, 
and found that the risk of VTE extended well beyond LOS in 
hospital with mean occurrence of VTE of 21.5 and 9.7 days 
after surgery for THA and TKA patients. Although that study 
had a very different set-up from our standardized fast-track 
scenario  with  prophylaxis  only  during  hospitalization,  we 
found much smaller risks of DVT. We believe that the uniform 
approach  with  spinal  anesthesia  and  multimodal  analgesia 
facilitating early mobilization may have been responsible for 
this difference. 
We found only 2 cases of DVT after day 30 (and within 90 
days), which coincides with the finding that on average symp-
tomatic DVT occurs 27 days and 17 days after THA and TKA 
(Dahl et al. 2000). Also, we found 1 of 2 cases of DVT in the 
proximal veins (proximal to the knee joint) in THA and 3 of 
9 cases of DVT in TKA, which corresponds with the findings 
of Dahl et al.
None of the patients developed PE from DVT within 90 
days, which is in accordance with the 2 studies by Kim et al. 
(2002, 2003) in which proximal thrombi after THA, TKA, 
and BSTKA were not found to be associated with pulmonary 
embolism,  even  without  treatment.  Dahl  et  al.  (2003)  also 
found only 6 of 50 patients with confirmed PE to have DVT. 
This may depend on genetic and prothrombotic factors (Kim 
and Kim 2007).
It should be emphasized that only clinically relevant DVT 
and PE requiring re-admission were included in our clinical 
study, as no routine ultrasound examinations were performed. 
This would lead to an underestimation of the total number of 
DVTs, as the clinically silent ones are not included. However, 
quite  a  few  patients  were  re-admitted  suspected  of  having 
DVT by their general practitioner. For every one with a posi-
tive ultrasound, 8 were negative, as we found only 11 DVTs 
during the 5 years. As all deaths are accounted for—and as 
PTS is of little clinical relevance—we have found that clini-
cally symptomatic DVT is a relevant outcome parameter.
We  encountered  no VTE-related  deaths,  no  PEs,  and  no 
DVTs in our study population of 123 patients operated with 
246 BSTKAs. The data on bilateral simultaneous total knee 
arthroplasty suggest that it is safe and has few complications, 
low mortality, and few VTEs in a fast-track setting with care-
ful selection of the patients (excluding every form of ischemic 
heart disease) (Kim et al. 2009).
It is both interesting and reassuring from our point of view 
that we have had no deaths due to VTEs during the last few 
years in this consecutive, unselected population, and that there 
is no inverse correlation between risk of VTEs and LOS, where 
the continuous reduction in LOS during the study period was 
associated with a shorter duration of prophylaxis. 
Our study has several strengths: (1) there was no selection 
bias since the patients were included in a continuous way 
based upon referral by the general practioners in the uptake 
area of the hospital; (2) The patients operated at our hospi-
tal are representative of THA and TKA patients; age, sex, 
co-morbidities etc. are typical of all patients and have been 
described in detail (Husted et al. 2008); (3) there was 100% 
follow-up; and (4) the results of our study can be expected to 
be the same in other departments, as our patients are typical 
unselected arthroplasty patients—provided that our fast-track 
protocol is copied. However, in our study only historical com-
parisons are given, as there have been no randomized con-
trolled trials (RCTs) on fast-track surgery with early mobiliza-
tion compared to a more conventional approach without early 
mobilization, despite the fact that early mobilization appears 
to be associated with lower rates of DVT (Pearse et al. 2007, 
Xing et al. 2008).
In conclusion, our fast-track THA and TKA regimen with 
early  mobilization  and  short  hospitalization—and  subse-604  Acta Orthopaedica 2010; 81 (5): 599–605
quently a very short duration of LMWH chemoprophylaxis—
resulted in very low risks of clotting-related death, PE, and 
DVT. This study was not designed (i.e. regarding the set-up 
and statistical power) to identify these parameters as the sole 
determinants of low risk of VTE, as the underlying reasons 
are  indeed  multifactorial.  Rodgers  et  al.  (2000),  Pearse  et 
al. (2007), and Xing et al. (2008) have suggested that earlier 
mobilization has an important role in reduction of VTE and 
our study appears to confirm this. A large, properly designed 
RCT with only the timing (and therefore the amount) of mobi-
lization after surgery varying between groups is needed to 
determine the true importance of mobilization (but it would 
require several thousand patients). 
As the risks of VTE in the present study were lower or com-
parable to the reported incidences in the literature from studies 
based on the recommended duration of prophylaxis of at least 
10 days for both THA and TKA, or up to 35 days for THA, we 
suggest that the principles of chemical thromboprophylaxis 
should be reconsidered, taking into account the clinical set-up, 
the time of first mobilization, and the length of hospital stay.
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